Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00769093
Recruitment Status : Terminated (Inadequate enrollment)
First Posted : October 8, 2008
Last Update Posted : April 21, 2017
National Cancer Institute (NCI)
AMAG Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Edward Neuwelt, OHSU Knight Cancer Institute

October 7, 2008
October 8, 2008
April 21, 2017
October 2008
July 2014   (Final data collection date for primary outcome measure)
  • The primary objective of this project is to describe quantitative imaging changes of brain tumor vascularity after anti-angiogenic therapy versus steroid therapy. This objective will be accomplished with the following aims and associated hypotheses. [ Time Frame: 15 weeks ]
  • To describe changes of quantitative blood brain barrier permeability measurements (Ktrans) of a standard gadolinium (Gd) MRI contrast between bevacizumab anti-angiogenic therapy and dexamethasone. [ Time Frame: 15 weeks ]
  • To describe relative cerebral blood volume (rCBV) changes obtained using ferumoxytol an iron oxide nanoparticle blood pool agent. [ Time Frame: 15 weeks ]
Same as current
Complete list of historical versions of study NCT00769093 on Archive Site
  • To assess vascular dynamic parameters (rCBV and Ktrans) values at progression. [ Time Frame: at progression ]
  • To describe the changes of the vascular dynamic parameters (rCBV, Ktrans) with the changes of standard gadolinium enhancing tumor volume [ Time Frame: 15 weeks ]
  • To describe post contrast tumor volume (enhancement) of gadolinium and ferumoxytol. [ Time Frame: 15 weeks ]
Same as current
Not Provided
Not Provided
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)
The purpose of this study is to learn more about imaging changes induced by a new therapeutic agent, bevacizumab with the standard steroid, dexamethasone in patients with high grade glioma. Magnetic resonance imaging (MRI) will be used to evaluate the difference between the 2 treatments. The usual contrast agent (gadolinium) and an iron containing contrast agent called "ferumoxytol" may help us to evaluate the differences between bevacizumab and dexamethasone effects on imaging of a brain tumor called high grade glioma. For this purpose, after intravenous contrast agent injection, special MR scans (called: dynamic perfusion, blood-brain barrier (BBB) permeability measurement) will be performed to see the microvascular changes in the brain and tumor.

Adult patients (>18 years old) with recurrent high grade glioma (confirmed by radiology and tissue sample), who have progressed on prior temozolomide + radiation therapy, will be recruited from the neurology, neurosurgery, or neuro-oncology clinics. Patients will be enrolled if they meet the study inclusion and exclusion criteria

Patients will be scanned at four different time-points (4 MRI series) (1) before the beginning of the treatment (base line), (2) Three weeks after the first treatment, (3) Three weeks after the second treatment, and (4) at time of progression of the disease. Each MRI time-point will consist of a series of MRI's on three consecutive days. On the first day, gadolinium (0.1 mmol/kg) will be injected for the MRI scan. On the following day ferumoxytol (2 mg/kg) and on the third day, the MRI scan will be done without additional contrast agent, to see the delayed contrast enhancement of ferumoxytol.

Subjects will be on treatment including a chemotherapeutic agent called carboplatin combined with either bevacizumab or dexamethasone; 6 patients will receive carboplatin-bevacizumab, followed by carboplatin-dexamethasone, another 6 patients will receive carboplatin- dexamethasone, followed by carboplatin-bevacizumab. After the 3rd time-point, all the patients will continue on carboplatin-bevacizumab treatment (which is currently not an FDA approved combination for brain tumors, however it is widely used throughout the country).There will be monthly clinical visits with clinical MRI until progression of the disease. There will be a follow up visit, 1 month after the last ferumoxytol injection.

Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Brain Neoplasms
Drug: Ferumoxytol
2 mg/kg
Other Name: AMAG Pharmaceuticals, Inc., Code 7228
  • Active Comparator: Group 1
    Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
    Intervention: Drug: Ferumoxytol
  • Active Comparator: Group 2
    Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
    Intervention: Drug: Ferumoxytol
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2014
July 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed Informed Consent Form
  • Age equal or greater than 18 years
  • Histologically confirmed high grade glioma
  • Radiographic demonstration of disease progression following prior therapy of temozolomide + radiation
  • Patient scheduled for bevacizumab + standard IV chemotherapy therapy
  • Bi-dimensionally measurable disease on gadolinium enhanced T1 weighted MR scans
  • An interval of at least 4 weeks since prior surgical resection
  • Patients corticosteroid dose must be 4 mg per day or less.
  • Karnofsky performance status greater than or equal to 50
  • Life expectancy greater than 12 weeks
  • Ability to comply with study and follow-up procedures

Exclusion Criteria:

  • Pregnant or nursing females
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Known liver function insufficiency, stage IV or V renal insufficiency
  • Disease and Treatment History: Prior treatment with bevacizumab, or another vascular endothelial growth factor (VEGF) or VEGFR-targeted agent; Need for urgent palliative intervention for primary disease (e.g., impending herniation
  • Bevacizumab Exclusion Criteria: History of hypertensive encephalopathy; New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF); History of myocardial infarction or unstable angina within 6 months prior to start of the study; History of stroke or transient ischemic attack within 6 months prior to study enrollment; Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to start of the study; Evidence of bleeding diathesis or coagulopathy; on therapeutic anti-coagulants.
  • Subjects unable to undergo an MRI with contrast
  • Ferumoxytol Exclusion Criteria: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol: parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations (Ferumoxytol Investigator's Drug Brochure, 2005). Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion
  • Subjects with known or suspected iron overload (genetic hemochromatosis or history of multiple transfusions).Patients with transferrin saturation greater than 60%
  • Inability or unwillingness to undergo the complete series of imaging sessions. Inability or unwillingness to return to the neuro-oncology clinic at Oregon Health and Science University (OHSU) for the one month follow-up
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
26XS293 ( Other Grant/Funding Number: NCI SAIC-Frederick Contract )
3678 ( Other Identifier: OHSU eIRB )
SOL-07083-LX ( Other Identifier: OHSU Knight Cancer Institute )
OHSU-3678 ( Other Identifier: OHSU IRB )
Not Provided
Not Provided
Edward Neuwelt, OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
  • National Cancer Institute (NCI)
  • AMAG Pharmaceuticals, Inc.
Principal Investigator: Edward A Neuwelt, MD Oregon Health and Science University
OHSU Knight Cancer Institute
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP